Filament Health signs letter of intent with Darmiyan to explore BrainSee AI in early Alzheimer's trial design

Aug 20, 2026 · Issue 3 · 2 sources, 2 articles

Filament Health, a wholly owned subsidiary of Rhelion Life Sciences, has signed a letter of intent with Darmiyan, Inc. to explore using the FDA De Novo authorized BrainSee AI platform in the design of an early Alzheimer's disease trial.

Who is affected and how

pharmaceuticals

An authorized AI tool could also play a role in selecting patients for trials.

Sources

• 2026-08-20 | Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design | CSE:RHEL | Press Releasestockhouse.com · Aug 20, 2026
• Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Designwebull.ca · Aug 20, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.